Sunday, 8 September 2024
  
Login

Australia's most trusted
source of pharma news

Sunday, 08 September 2024
Listen to this story 
News

DNA giant backs psilocybin drug

Posted 24 July 2024 PM

DNA giant Illumina is getting behind Incannex's psilocybin candidate, offering its genomic technologies to a Monash research team investigating the drug to treat generalised anxiety disorder (GAD).

Dr Andrew Gibbons from the Department of Psychiatry, School of Clinical Sciences at Monash Health has been named the winner of the annual Australasian Neuroscience Society (ANS) Illumia Neurogenomics Research Award.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (22)

Clinical & Medical, R&D (13)

Regulatory, Pharmacovigilance & QA (6)

Other (10)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.